LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital ...

It is a world-first that pure semaglutide processed with DehydraTECH technology without SNAC will be compared directly to SNAC-enabled Rybelsus® in a multiple week human study. Is DehydraTECH ...

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

This week, Novo Nordisk announced that people taking its mega-dose version of semaglutide lost substantially more body weight than usual in a large-scale trial. Novo Nordisk’s STEP UP trial ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

A new study shows that semaglutide can improve glucose levels for people with type 1 diabetes who use automated pumps, without increasing hypoglycemia. In this double-blinded randomized trial ...